Skip to content
ApprovedFDA approvedStrong evidence

L‑DOPA

Prescription Parkinson's medicine, the direct precursor of dopamine, which is turned into dopamine in the brain.

DopaminergicAmino AcidDopaminergicMoodDopamineNorepinephrinenoo.affects.moodnoo.affects.focus
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassDopaminergic · Mood
Primary targetAromatic L-amino acid decarboxylase substrate (direct dopamine precursor)
Targets5 receptor targets
Half-lifeShort, roughly 1-2 hours without a decarboxylase inhibitor (somewhat extended with carbidopa)
OnsetAbout 30-60 minutes on an empty stomach; a high-protein meal slows absorption
EvidenceStrong evidence
Affected systemsDopamineNorepinephrinenoo.affects.moodnoo.affects.focus

Contents

DETAILED OVERVIEW

What is L-DOPA?

L-DOPA (levodopa) is a prescription medicine and has been the mainstay treatment for Parkinson's disease for decades; both the American and the European authorities have approved it. It is not a freely available dietary supplement; velvet bean (Mucuna pruriens) extracts contain natural L-DOPA, but they are unregulated.

Dopamine itself cannot cross the blood-brain barrier, but L-DOPA can, and it is turned into dopamine in the brain. So it replaces the dopamine that is depleted in Parkinson's disease, which makes it the most effective treatment for the movement symptoms. It is almost always given together with carbidopa or benserazide. In the short term it may also boost motivation and drive, which is why it is tried as a nootropic, but adaptation of the dopamine system and a rebound effect make it unsuitable for sustained self-treatment. It can cause nausea, dizziness, involuntary movements with longer use, hallucinations and, rarely, impulse-control problems (such as gambling). Together with non-selective MAO inhibitors it can cause a dangerous rise in blood pressure.

Mechanism

Dopamine precursor; crosses the blood-brain barrier, then becomes dopamine

Half-life

Short, roughly 1-2 hours without a decarboxylase inhibitor

Legal status

Prescription drug (FDA/EMA approved)

Receptor profile

  • Aromatic L-amino acid decarboxylase (AADC)Strong
  • Brain dopamine levelsStrong
  • Dopamine receptors (indirect, via conversion to dopamine)Strong
  • Norepinephrine synthesisModerate
  • Prolactin (lowers)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Nausea and vomiting, especially early in treatment (peripheral dopamine stimulates the vomiting centre)
  • Orthostatic hypotension, dizziness, light-headedness on standing
  • Dyskinesias (involuntary movements) and motor fluctuations (wearing-off, on-off phenomenon) with long-term use
  • Psychiatric effects: vivid dreams, hallucinations, confusion, rarely impulse-control disorders (gambling, hypersexuality)
  • Loss of appetite, dry mouth, harmless darkening of urine and sweat
  • Somnolence, sudden sleep attacks at higher doses

Contraindications · 5

  • Narrow-angle (closed-angle) glaucoma: the catecholaminergic effect can worsen it
  • Concurrent non-selective MAO inhibitors: risk of hypertensive crisis (a washout of at least 2 weeks is required)
  • Known or suspected melanoma or undiagnosed skin lesions
  • Severe cardiovascular, hepatic or renal disease, or psychotic disorder without medical supervision
  • Pregnancy and breastfeeding: safety not established, only under clear medical indication

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

L-DOPA (levodopa) is the cornerstone drug for Parkinson's disease, used for decades, because it replenishes the dopamine that becomes deficient in the brain in these patients, something dopamine itself cannot do since it can't get into the brain. It's the most effective treatment for Parkinson's motor symptoms like rigidity, tremor and slowed movement, and can also give a short-term boost to motivation and drive. It's usually taken combined with another agent (carbidopa or benserazide) so more of it reaches the brain and it causes less nausea.

Telegram

Have a question about L‑DOPA?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeDopaminergic
FormulaC9H11NO4
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.